The American Liver Foundation (ALF) has launched a toolkit — featuring a plush lion named Bili the Brave — to support children and families…
News
HEPATITIS
NewsAbbvie pulls 2 hepatitis treatments from EU market
Abbvie has decided to permanently discontinue the marketing of antiviral treatments Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) for adults with chronic hepatitis…
CHOLANGITIS
NewsIqirvo approved in UK for adults with PBC, problems with UDCA
U.K. regulators have approved Iqirvo (elafibranor) for adults with primary biliary cholangitis (PBC) who fail to respond to or cannot tolerate first-line…
CHOLESTASIS
NewsIVF linked to higher rates of cholestasis pregnancy complication
Women who conceive with the help of in vitro fertilization (IVF) — a commonly used assisted reproductive technology — are almost three times more likely…
FATTY LIVER DISEASE
NewsFDA gives denifanstat for MASH breakthrough therapy status
The U.S. Food and Drug Administration (FDA) has given breakthrough therapy designation to denifanstat, Sagimet Biosciences’ investigational oral therapy for metabolic dysfunction-associated steatohepatitis…
ALAGILLE SYNDROME
NewsKayfanda wins EU OK for Alagille-related cholestatic pruritus
Ipsen’s Kayfanda (odevixibat) has been approved, under exceptional circumstances, in the European Union (EU) to treat cholestatic pruritus in people with Alagille syndrome,…
LIVER DISEASE
NewsLiver Foundation plans activities, events for Liver Awareness Month
October is National Liver Awareness Month, and the American Liver Foundation (ALF) is promoting a series of activities and events to call attention to…
CHOLANGITIS
NewsCNP-104 shown to safely reduce liver scarring in PBC Phase 2 trial
Two infusions of the investigational therapy CNP-104 safely reduced liver scarring (fibrosis) and led to beneficial changes in disease-related immune cell populations among adults with…
CHOLESTASIS
NewsCase study supports efficacy of biliary diversion surgery for PFIC4
Biliary diversion surgery — which can be used in patients with bile duct problems — successfully reduced markers of liver damage, lessened itching, and improved…
FATTY LIVER DISEASE
NewsLanifibranor may be reason for liver gains seen in Phase 3 MASH trial
Signs of improved liver health are evident in biomarker and liver scarring assessments of people with metabolic-associated steatohepatitis or MASH — a severe form of…
Recent Posts
- Living with MASH reminds me to avoid making assumptions
- Particles in grilled meats may trigger liver disease, mouse study finds
- Supporting my oldest son, who’s growing up with a chronically ill sibling
- Human trial testing gene silencing injection therapy for MASH kicks off
- Blood bile acids predict liver outcomes in Alagille syndrome children: Study